Impact of Altitude on Anemia, Erythropoietin-Stimulating Agent, and Intravenous Iron Requirement in Hemodialysis Patients.
Yazarlar (11)
Cebrail Karaca
Selma Alagoz
Aydan Mutis Alan
Beyza Nur Aydin Keskin
Saadet Usakli
Mert Kantarci
Prof. Dr. Mehmet Emin ERDEM Sinop Üniversitesi, Türkiye
Mahir Coskun
Mevlut Tamer Dincer
Nurhan Seyahi
Prof. Dr. Sinan Trabulus Sinop Üniversitesi
Makale Türü Açık Erişim Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale)
Dergi Adı Eastern Journal of Medicine
Makale Dili Basım Tarihi 10-2023
Cilt / Sayı / Sayfa 28 / 4 / 765–771 DOI
Makale Linki https://jag.journalagent.com/z4/download_fulltext.asp?pdir=ejm&plng=tur&un=EJM-06337
UAK Araştırma Alanları
Su Ürünleri İşleme Teknolojileri
Özet
Anemia is an important cause of morbidity and mortality in chronic kidney disease (CKD). Previous studies have shown the curative effects of altitude on anemia in hemodialysis (HD) and non-hemodialysis CKD. This study examined the effect of altitude on erythropoietin stimulating agent (ESA), İntravenous (IV) iron requirement in HD patients. This retrospective observational study was conducted between January and June 2023. The study group was divided into two groups according to altitude: HD patients living in Van Province (1,730 meters, 5,765 feet) in the high-altitude group (HAG) and HD patients living in Istanbul Province (sea level) in the low-altitude group (LAG). In addition to hemoglobin (Hgb) and ferritin levels, ESA and IV iron doses were recorded at monthly visits for six months. These values of the HAG and LAG were compared.A total of 184 patients were included in the study (HAG: 108 patients and LAG: 79 patients). HD patients living at high altitudes had statistically significantly higher Hgb and ferritin values compared to low altitudes (HAG: 11.5 g/dL, 749 pg/L vs. LAG: 11.3 g/dL; 543 pg/L; p= 0.04, p< 0.001, respectively). In addition, ESA (HAG: 53 IU/kg/week, 12000 IU/month vs. LAG: 100.6 IU/kg/week, 24000 IU/month; p< 0.001) and IV iron (HAG: 208.3±151 mg/month vs. LAG: 364.9±300.8 mg/month; p= 0.002) dose was significantly lower. HD patients living at high altitude needed lower doses of ESA and IV iron to reach higher Hgb values than patients living at lower altitude.
Anahtar Kelimeler
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Google Scholar 4

Paylaş